CoChat
Sign Up
Cited by 36Cervical Cancer and HPV ResearchReproductive tract infections researchWomen's cancer prevention and management

Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

Open access
Nygård, Mari, Hansen, Bo T., Kjaer, Susanne K., Hortlund, Maria, Tryggvadóttir, Laufey, Munk, Christian, Lagheden, Camilla, Sigurdardottir, Lara G. +3 more·2021·Human Vaccines & Immunotherapeutics
DOI 10.1080/21645515.2020.1814097PMC PMC8018444
Open this paper in CoChat — free accountOpen PDF

Abstract

Prevalence of different HPV genotypes is changing after HPV vaccination. The associated risks are needed for optimizing cervical cancer screening.To estimate HPV type-specific prevalence, odds ratio (OR), and positive predictive value (PPV) for cervical cytological abnormalities, we determined 41 different HPV genotypes in cervical samples from a population-based sample of 8351 women aged 18-51 years before HPV vaccination era (V501-033; NCT01077856).Prevalence of HPV16 was 4.9% (95% CI: 4.4-5.5) with the PPV for high-grade cytology 11.2%, and OR 11.9 (95% CI: 8.5-16.5). Carcinogenic HPVs included in the nonavalent vaccine (HPV16,18,31,33,45,52,58) had a population prevalence of 14.4% (95% CI: 13.5-15.4), with PPV of 8.0% (95% CI: 6.8-9.3) and OR 23.7 (95% CI: 16.0-63.5) for high-grade cytology. HPV types currently included in most screening tests, but not vaccinated against (HPV35,39,51,56,59,66,68) had a joint prevalence of 8.5% (95% CI: 7.8-9.2) with PPV of 4.4% (95% CI: 3.3-5.7) and OR of 2.9 (95% CI: 2.0-4.0) for high-grade cytology. The other 27 non-carcinogenic genotypes had a prevalence of 11.8%, PPV of 2.9% (95% CI:2.1-3.9), and OR 1.5 (95% CI: 1.1-2.2.) for high-grade cytology.These results suggest that HPV screening tests in the post-vaccination era might perform better if restricted to the HPV types in the nonavalent vaccine and screening for all 14 HPV types might result in suboptimal balance of harms and benefits.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2020.1814097

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002; 2(5): 342– 50. doi: 10.1038/nrc798. 12044010 · DOI
  2. [2]Kinney WK, Perkins RB, Sawaya GF. Equal management of equal risks: what should be used as the standard for cervical cancer prevention? J Low Genit Tract Dis. 2018; 22(3): 237– 41. doi: 10.1097/LGT.0000000000000402. 29794532 PMC6023600 · DOI
  3. [3]IARC Working group. IARC handbooks of cancer prevention: cervix cancer screening. Vol. 10. Lyon (France): IARC Press; 2005. Available at http://publications.iarc.fr/Book-And-Report-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervix-Cancer-Screening-2005
  4. [5]Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320(7): 687– 705. doi: 10.1001/jama.2018.10400. 30140883 PMC13387487 · DOI
  5. [6]Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018; 66(3): 339– 45. doi: 10.1093/cid/cix797. 29029053 · DOI
  6. [7]Lehtinen M, Lagheden C, Luostarinen T, Eriksson T, Apter D, Harjula K, Kuortti M, Natunen K, Palmroth J, Petäjä T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials. BMJ Open. 2017; 7(8): e015867. doi: 10.1136/bmjopen-2017-015867. PMC5629648 28821519 · DOI
  7. [8]Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012; 30(Suppl 5): F123– 138. doi: 10.1016/j.vaccine.2012.04.108. 23199956 PMC4636904 · DOI · Paper page
  8. [9]Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh P, Ferreccio C, Hieu NT, Matos E, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005; 366(9490): 991– 98. doi: 10.1016/S0140-6736(05)67069-9. 16168781 · DOI
  9. [10]de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007; 7(7): 453– 59. doi: 10.1016/S1473-3099(07)70158-5. 17597569 · DOI · Paper page
  10. [11]Bzhalava D, Guan P, Franceschi S, Dillner J, Clifford G. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology. 2013; 445(1–2): 224– 31. doi: 10.1016/j.virol.2013.07.015. 23928291 · DOI
  11. [13]Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013; 22(4): 553– 60. doi: 10.1158/1055-9965.EPI-12-1406. 23549399 PMC3711590 · DOI
  12. [14]Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102(19): 1478– 88. doi: 10.1093/jnci/djq356. 20841605 PMC2950170 · DOI
  13. [15]Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008; 337: a1754. doi: 10.1136/bmj.a1754. 18852164 PMC2658827 · DOI · Paper page
  14. [16]IARC Working Group. IARC Monographs - 100B: human Papillomaviruses. Lyon (France): WHO Press: International agency for research on cancer; 2012. http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-11.pdf.
  15. [17]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009; 10(4): 321– 22. doi: 10.1016/S1470-2045(09)70096-8. 19350698 · DOI · Paper page
  16. [18]Pedersen K, Burger EA, Nygard M, Kristiansen IS, Kim JJ. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018; 91: 68– 75. doi: 10.1016/j.ejca.2017.12.018. 29335156 PMC5803338 · DOI
  17. [19]Petry KU, Bollaerts K, Bonanni P, Stanley M, Drury R, Joura E, Kjaer SK, Meijer CJLM, Riethmuller D, Soubeyrand B, et al. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine. Hum Vaccin Immunother. 2018; 14(7): 1800– 06. doi: 10.1080/21645515.2018.1450125. 29553886 PMC6067852 · DOI
  18. [20]Nygard M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw K-L, Dasbach EJ, Kjær SK, et al. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. PLoS One. 2014; 9(2): e88323. doi: 10.1371/journal.pone.0088323. 24505474 PMC3914976 · DOI
  19. [21]Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013; 40(2): 130– 35. doi: 10.1097/OLQ.0b013e31827bd66b. 23324976 · DOI
  20. [22]Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia–nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014; 106(3): djt460. doi: 10.1093/jnci/djt460. 24552678 · DOI
  21. [23]Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, Arnheim-Dahlström L, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013; 105(7): 469– 74. doi: 10.1093/jnci/djt032. 23486550 PMC3614506 · DOI
  22. [24]Feiring B, Laake I, Bakken IJ, Greve-Isdahl M, Wyller VB, Håberg SE, Magnus P, Trogstad L. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway. Vaccine. 2017; 35(33): 4203– 12. doi: 10.1016/j.vaccine.2017.06.031. 28648542 · DOI
  23. [25]Vaccarella S, Franceschi S, Engholm G, Lonnberg S, Khan S, Bray F. 50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence. Br J Cancer. 2014; 111(5): 965– 69. doi: 10.1038/bjc.2014.362. 24992581 PMC4150271 · DOI
  24. [26]Elfstrom KM, Sparen P, Olausson P, Almstedt P, Strander B, Dillner J. Registry-based assessment of the status of cervical screening in Sweden. Journal of Medical Screening. 2016; 23(4): 217– 26. doi: 10.1177/0969141316632023. 27068429 · DOI
  25. [27]Solomon D, Nayar R. The Bethesda System for reporting cervical cytology. Second. New-York, USA: Springer-Verlag New-York, Inc.; 2004.
  26. [28]Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Törnberg S, Dillner J, Dillner L. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol. 2011; 205(2): 145e1– 16. doi: 10.1016/j.ajog.2011.03.056. 21658668 · DOI
  27. [29]Eliasen M, Kaer SK, Munk C, Nygård M, Sparén P, Tryggvadottir L, Liaw K-L, Grønbæk M. The relationship between age at drinking onset and subsequent binge drinking among women. Eur J Public Health. 2009; 19(4): 378– 2. doi: 10.1093/eurpub/ckp023. 19321715 · DOI
  28. [30]Hansen BT, Kjaer SK, Munk C, Tryggvadottir L, Sparén P, Hagerup-Jenssen M, Liaw K-L, Nygård M. Early smoking initiation, sexual behavior and reproductive health - a large population-based study of Nordic women. Prev Med. 2010; 51(1): 68– 72. doi: 10.1016/j.ypmed.2010.03.014. 20353801 · DOI
  29. [31]Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, NYGÅRD M, KJAER SK. Women’s sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand. 2011; 90(5): 459– 67. doi: 10.1111/j.1600-0412.2010.01066.x. 21306319 · DOI
  30. [32]Olesen TB, Jensen KE, Nygard M, Tryggvadottir L, Sparén P, Hansen BT, Liaw K-L, Kjaer SK. Young age at first intercourse and risk-taking behaviours–a study of nearly 65 000 women in four Nordic countries. Eur J Public Health. 2012; 22(2): 220– 24. doi: 10.1093/eurpub/ckr055. 21596800 · DOI · Paper page
  31. [35]Korn EL, Graubard BI. Confidence intervals for proportions with small expected number of positive counts estimated from survey data. Surv Methodol. 1998; 24: 193– 201.
  32. [36]Lewandowski GS, Vaccarello L, Copeland LJ. Surgical issues in the management of carcinoma of the cervix in pregnancy. Surg Clin North Am. 1995; 75(1): 89– 100. doi: 10.1016/S0039-6109(16)46536-9. 7855721 · DOI
  33. [37]Orumaa M, Kjaer SK, Dehlendorff C, Munk C, Olsen AO, Hansen BT, Campbell S, Nygård M. The impact of HPV multi-cohort vaccination: real-world evidence of faster control of HPV-related morbidity. Vaccine. 2020; 38(6): 1345– 51. doi: 10.1016/j.vaccine.2019.12.016. 31917039 · DOI
  34. [38]Bonde J, Rebolj M, Ejegod DM, Preisler S, Lynge E, Rygaard C. HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 human papillomavirus genotype microarray system. BMC Infect Dis. 2014; 14(1): 413. doi: 10.1186/1471-2334-14-413. 25064473 PMC4122758 · DOI
  35. [39]Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010; 202(12): 1789– 99. doi: 10.1086/657321. 21067372 · DOI
  36. [40]von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, Patnick J, Ronco G, Segnan N, Suonio E, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 2015; 1: 22– 31. doi: 10.1016/j.pvr.2015.06.006. · DOI · Paper page
  37. [41]Hashim D, Engesaeter B, Baadstrand Skare G, Castle PE, Bjørge T, Tropé A, Nygård M. Real-world data on cervical cancer risk stratification by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer. 2020; 122(11): 1715– 23. doi: 10.1038/s41416-020-0790-1. 32242098 PMC7250848 · DOI
  38. [42]Lee EH, Um TH, Chi HS, Hong YJ, Cha YJ. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay. J Korean Med Sci. 2012; 27(9): 1091– 97. doi: 10.3346/jkms.2012.27.9.1091. 22969258 PMC3429829 · DOI
  39. [43]Chan PK, Ho WC, Yu MY, Pong WM, Chan AC, Chan AK, Cheung T-H, Wong MCS, To K-F, Ng H-K, et al. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer. 2009; 125(7): 1671– 77. doi: 10.1002/ijc.24495. 19507252 · DOI
  40. [44]Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(10): 781– 89. doi: 10.1016/S1473-3099(12)70187-1. 22920953 · DOI
  41. [45]Hansen BT, Kjaer SK, Arnheim-Dahlstrom L, Liaw KL, Juul KE, Thomsen LT, Frederiksen K, Elfström KM, Munk C, Nygård M, et al. Age at first intercourse, number of partners and sexually transmitted infection prevalence among Danish, Norwegian and Swedish women: estimates and trends from nationally representative cross-sectional surveys of more than 100 000 women. Acta Obstet Gynecol Scand. 2020; 99(2): 175– 85. doi: 10.1111/aogs.13732. 31529491 · DOI
  42. [46]Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, Garland SM, Chen MY, Fairley CK. Human papillomavirus in young women with chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infect Dis. 2015; 15(11): 1314– 23. doi: 10.1016/S1473-3099(15)00055-9. 26201300 · DOI
  43. [47]Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2017; 142(4): 709– 18. doi: 10.1002/ijc.31094. 29023748 PMC5765470 · DOI
  44. [48]Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006; 110(5): 525– 41. doi: 10.1042/CS20050369. 16597322 · DOI · Paper page
  45. [49]Egawa N, Egawa K, Griffin H, Doorbar J. Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015; 7(7): 3863– 90. doi: 10.3390/v7072802. 26193301 PMC4517131 · DOI
  46. [50]Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jerónimo J, Wacholder S, Rodríguez AC, Morales J, Hutchinson M, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26(4): 441– 46. doi: 10.1097/pgp.0b013e31805152ab. 17885496 · DOI
  47. [51]Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, O’Sullivan JP, Summerell JM, Newcombe RG. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989; 298(6675): 707– 10. doi: 10.1136/bmj.298.6675.707. 2496816 PMC1835992 · DOI
  48. [52]Robertson AJ, Anderson JM, Beck JS, Burnett RA, Howatson SR, Lee FD, Lessells AM, McLaren KM, Moss SM, Simpson JG, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989; 42(3): 231– 38. doi: 10.1136/jcp.42.3.231. 2539400 PMC1141860 · DOI
  49. [53]Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Jama. 2001; 285(11): 1500– 05. doi: 10.1001/jama.285.11.1500. 11255427 · DOI · Paper page
  50. [55]Dillner J, Nygard M, Munk C, Hortlund M, Hansen BT, Lagheden C, Liaw K-L, Kjaer SK. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018; 36(26): 3820– 29. doi: 10.1016/j.vaccine.2018.05.019. 29778519 · DOI

Cited by

Sorted by citations

Authors
Nygård, M., Hansen, B. T., Kjaer, S. K., Hortlund, M., Tryggvadóttir, L., Munk, C., Lagheden, C., Sigurdardottir, L. G., Campbell, S., Liaw, K.-L., & Dillner, J.
Affiliations
  • Cancer Registry of Norway (NO)
  • Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
  • Karolinska Institutet (SE)
  • Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland
  • Danish Cancer Society (DK)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Nygård, Mari
ORCID
Venue
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Published
2020-09-29
Volume
17
Issue
4
Pages
972-981
ISSN
  • 2164-5515 (ISSN-L)
  • 2164-554X
DOI
10.1080/21645515.2020.1814097
PMC
PMC8018444
OpenAlex
W3089984332
Cited by
36
References
1
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 13 · 2022: 4 · 2021: 4
FWCI
3.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Merck Sharp & Dohme Corp (NCT01077856)
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
human papillomavirus, HPV genotypes, cervical intraepithelial lesions, cervical cancer screening, HPV16, nonavalent HPV vaccine, HPV prevalence, positive predictive value
MeSH terms
Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female, Genotype, Humans, Papillomaviridae, Papillomavirus Infections, Human papillomavirus 16, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review